AstraZeneca PLC (AZN)vsViemed Healthcare Inc (VMD)
AZN
AstraZeneca PLC
$185.95
-0.83%
HEALTHCARE · Cap: $282.69B
VMD
Viemed Healthcare Inc
$9.56
+0.84%
HEALTHCARE · Cap: $382.22M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 20991% more annual revenue ($60.44B vs $286.56M). AZN leads profitability with a 17.2% profit margin vs 5.2%. VMD trades at a lower P/E of 26.9x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
VMD
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Margin of Safety
+24.6%
Fair Value
$11.20
Current Price
$9.56
$1.64 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Revenue surging 27.5% year-over-year
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Moderate valuation
0.0% earnings growth
Smaller company, higher risk/reward
5.2% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : VMD
The strongest argument for VMD centers on Debt/Equity, Altman Z-Score, Price/Book. Revenue growth of 27.5% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : VMD
The primary concerns for VMD are P/E Ratio, EPS Growth, Market Cap.
Key Dynamics to Monitor
AZN profiles as a mature stock while VMD is a growth play — different risk/reward profiles.
VMD carries more volatility with a beta of 1.13 — expect wider price swings.
VMD is growing revenue faster at 27.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 48/100), backed by strong 17.2% margins and 12.5% revenue growth. VMD offers better value entry with a 24.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Viemed Healthcare Inc
HEALTHCARE · MEDICAL DEVICES · USA
Viemed Healthcare, Inc. provides durable home medical equipment and post-acute respiratory health care services to patients in the United States. The company is headquartered in Lafayette, Louisiana.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?